Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CEN Case Reports
Published in: CEN Case Reports 3/2020

01-08-2020 | Kidney Transplantation | Case Report

Retransplantation after post transplant lymphoproliferative disorder: overcoming the obstacles!

Authors: Pallavi Prasad, Dinesh Khullar, Nimish Gupta, Rahul Grover, Gagandeep Chhabra, Kunal Raj Gandhi, Sagar Gupta, Sahil Bagai

Published in: CEN Case Reports | Issue 3/2020

Login to get access

Abstract

Post transplant lymphoproliferative disorder (PTLD) is a rare complication after kidney transplantation. Graft dysfunction is often encountered during the course of the treatment of PTLD, at times leading to need for retransplantation. We describe here the case of a young boy who underwent retransplantation after treatment of early Epstein Barr virus (EBV) related post transplant lymphoproliferative disorder. Our case highlights the various factors needing deliberation before retransplantation including time from remission of PTLD, EBV serostatus and choice of induction and maintenance immunosuppression agents.
Literature
1.
Johnson SR, Cherikh WS, Kauffman HM, et al. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant. 2006;6:2743–9.CrossRef
2.
Caillard S, Cellot E, Dantal J, et al. A French cohort study of kidney retransplantation after post-transplant lymphoproliferative disorders. Clin J Am Soc Nephrol. 2017;12:1663–700.CrossRef
3.
Abe T, Ichimaru N, Kokado Y, et al. Post-transplant lymphoproliferative disorder following renal transplantation: a single-center experience over 40 years. Int J Urol. 2010;17(1):48–544.CrossRef
4.
Chan TS, Hwang YY, Gill H, et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant. 2012;26(5):679–83.CrossRef
5.
Cheung CY, Ma MKM, Chau KF, et al. Posttransplant lymphoproliferative disorders in kidney transplant recipients: a retrospective cohort analysis over two decades in Hong Kong. Oncotarget. 2017;8(57):96903–12.CrossRef
6.
Parker A, Bowles K, Bradley A, et al. Haematooncology task force of the British Committee for Standards in Haematology and British Transplantation Society: Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS guidelines. Br J Haematol. 2010;149:693–705.CrossRef
7.
Hanto DW. Retransplantation after post-transplant lymphoproliferative diseases (PTLD): when is it safe? Am J Transplant. 2004;4:1733–4.CrossRef
8.
Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5:2894–900.CrossRef
9.
Reddy N, Rezvani K, Barrett J, et al. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011;17(5):591–7.CrossRef
Metadata
Title
Retransplantation after post transplant lymphoproliferative disorder: overcoming the obstacles!
Authors
Pallavi Prasad
Dinesh Khullar
Nimish Gupta
Rahul Grover
Gagandeep Chhabra
Kunal Raj Gandhi
Sagar Gupta
Sahil Bagai
Publication date
01-08-2020

Other articles of this Issue 3/2020

CEN Case Reports 3/2020 Go to the issue

Case Report

Ask-Upmark kidney in a girl with neurofibromatosis type 1

Case Report

Hypersensitivity reactions to bicarbonate dialysate containing acetate: a case report with literature review

Case Report

Incidental detection of Corynebacterium jeikeium endocarditis via regular blood examination in an afebrile hemodialysis patient

Correction

Correction to: Dietary potassium restriction attenuates urinary sodium wasting in the generalized form of pseudohypoaldosteronism type 1

Case Report

Contrast medium-induced severe thrombocytopenia in patient on maintenance hemodialysis: a case report and literature review

Case Report

Induction of hemodialysis with an arteriovenous fistula in a patient with hemophilia A
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits